We continue to engage in strategic donations to address access gaps for neglected diseases and people at the bottom of the pyramid. These include our long-term programs to deliver essential medicines for infectious diseases such as leprosy.
The Glivec International Patient Assistance Program
Recognizing from the beginning the critical importance of breakthrough cancer therapy, Novartis Oncology immediately mobilized efforts globally to ensure access to medicines for patients in need. We also developed patient and healthcare professional education and personal support programs that are valuable in maximizing treatment success.
In 2002, Novartis Oncology introduced the Glivec® International Patient Assistance Program (GIPAP™), providing medicines by full donation to properly diagnosed patients in countries around the world without government or private reimbursement and who are unable to pay for the medication. Well over USD 1 billion worth of medicines have been donated since the inception of the program in 2001.
In late 2017, the CMLPath to Care™ collaboration replaced GIPAP with a new, independent, patient-centered access model. Under the new initiative, The Max Foundation, a global, patient-focused, non-governmental organization (NGO), assumed from Novartis the responsibility for delivering treatments to these patients, including supply chain management. Novartis provides funding and drug donation support. The collaborative agreement runs through Q1 2021 with an option to extend. During this timeframe, Novartis expects to donate more than USD 29 million to the collaboration, along with approximately 315,000,000 doses of medicine.
Over the past 30 years, more than 15 million leprosy patients have been treated and the incidence of the disease has declined significantly – a tremendous public health success. Since 2000, Novartis has helped fight the disease by donating Novartis multidrug therapy (MDT) to leprosy patients worldwide through the World Health Organization.
In 2015, we renewed our pledge to work to end leprosy by extending our donation of MDT medicines through 2020. This five-year agreement includes treatments worth more than USD 40 million and up to USD 2.5 million to support the WHO in handling the donation and logistics. Overall, it is expected that the program will reach an estimated 1.3 million patients during its five-year term. This is part of the company's commitment in 2012 to the London Declaration on Neglected Tropical Diseases.
Since 2005, Novartis has provided Egaten® free of charge through the WHO to people with fascioliasis worldwide. Since the start of the donation program, Novartis has donated approximately 4 million tablets of Egaten, valued at USD 41 million, helping to treat around 2 million people with fascioliasis in more than 30 countries. In 2018, Novartis reaffirmed its commitment to the fight against fascioliasis, signing a renewed memorandum of understanding with the WHO to extend the Egaten drug donation until 2022.
Donation programs for disaster relief
In the case of a disaster, we work with the international community and our local country organizations on the ground. Our aim is to deliver our support as quickly as possible in order to achieve the greatest possible impact for those directly affected.
Our Disaster Relief Process enables us to make timely decisions (within 72 hours after an event strikes) and deliver aid in a sustainable and transparent manner based on the needs of affected communities. Depending on the situation, our aid includes medicine donations, funds and/or matching gift programs.
As a first priority, two categories of Novartis drugs are made available: antibiotics and analgesics. All our drug donations comply with the WHO’s checklist for Drug Donations. Beyond drugs, Novartis is guided by the Emergency Health Kit list provided by the IDA Foundation.